Optometrists in Saraland, AL Accepting Medicare

6 Optometrists found. Showing 1 - 6

Optometry Exchange Of Alabama, Inc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1088 Industrial Pkwy, Saraland, AL 36571 Phone: 251-675-3666

Phillip R Gillette Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1088 Industrial Pkwy Ste 4, Saraland, AL 36571 Phone: 251-675-3666    Fax: 251-675-9366

The Lens Doc, Llc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1088 Industrial Pkwy Ste 4, Saraland, AL 36571 Phone: 251-675-3666    Fax: 251-675-9366

Dr. Layle Dean Boatwright, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1095 Industrial Pkwy, Saraland, AL 36571 Phone: 251-675-0841    Fax: 251-679-4109

T Jefferson Hicks Od Pc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1127 Highway 43 S, Saraland, AL 36571 Phone: 251-675-2718

Thomas Jefferson Hicks, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1127 Highway 43 South, Saraland, AL 36571 Phone: 251-675-2718    Fax: 251-675-9827

News Archive

Fourth-quarter and fiscal year end 2009 results announced by Palatin Technologies

Palatin Technologies, Inc. (NYSE Amex: PTN) today announced results for its fourth quarter and fiscal year ended June 30, 2009. For the year ended June 30, 2009, total revenues were $11.4 million, compared to $11.5 million for year ended June 30, 2008. Palatin's net loss for the year ended June 30, 2009 was $4.8 million, or $(0.06) per basic and diluted share, compared to a net loss of $14.4 million, or $(0.17) per basic and diluted share, for the year ended June 30, 2008.

Actavis commences distribution of Methylphenidate Hydrochloride Extended-Release Capsules

Actavis Group, an international generic pharmaceuticals company, today announced that it recently received approval from the US Food & Drug Administration to market Methylphenidate Hydrochloride Extended-Release Capsules (LA) CII, USP, 20mg, 30mg, and 40mg. Actavis has first-to-file exclusivity on the 20mg, 30mg, and 40mg strengths.

CRF announces additional featured trials to be presented at Transcatheter Cardiovascular Therapeutics 2010

The Cardiovascular Research Foundation has announced that in addition to the previously announced late breaking clinical trials and first reports, a series of additional featured trials will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 scientific symposium. These trials will focus on a wide range of significant topics in interventional cardiovascular medicine. TCT 2010 will take place September 21 - 25 in Washington, DC.

Positive results from Aerie Pharmaceuticals' Phase 2a study of its Rho-kinase inhibitor

Aerie Pharmaceuticals, a biotechnology company focused on the discovery and development of novel treatments for glaucoma, today announced positive results from a Phase 2a study of its Rho-kinase (ROCK) inhibitor, AR-12286. The study evaluated the safety, tolerability and efficacy of three different doses of AR-12286 in 88 patients with primary open angle glaucoma or ocular hypertension.

LifeBridge Health's Neil Meltzer wins AHA Gold Heart Award

The Gold Heart Award, the American Heart Association's highest national recognition for volunteerism, was presented to Neil Meltzer, M.P.H., president and CEO of LifeBridge Health, for his two decades of exceptional leadership and advocacy at the annual Gold Heart Banquet in Dallas, Texas.

Read more Medical News

› Verified 4 days ago